NO/LAAN Newsletter : Q3 2023
The NO/LA Angel Network's Fall 2023 Newsletter is here! Please click to learn more about NO/LAAN’s third quarter of 2023 and to sign-up for future newsletters.
NO/LAAN Newsletter : Q2 2023
The NO/LA Angel Network's Summer 2023 Newsletter is here! Please click to learn more about NO/LAAN’s second quarter of 2023 and to sign-up for future newsletters.
2023 NOLAAN Investor Conference Sponsorships
The NO/LA Angel Network's Annual Investor Conference will take place November 9 - 10, 2023. If you have interest in becoming a sponsor for this conference, we are offering multiple tiers of sponsorship with a variety of sponsor-benefits. Please take a look at our...
NO/LAAN Newsletter : Q1 2023
The NO/LA Angel Network is proud to announce the beginning of our quarterly newsletter! Please click to learn more about NO/LAAN's first quarter of 2023 and to sign-up for future newsletters.
BioAesthetics and Tulane awarded grant to develop new advanced wound-care graft
From news.tulane.edu The National Science Foundation has awarded a $250,000 grant to BioAesthetics Corp. to develop a new advanced wound-care product for treating bed sores or pressure ulcers. The product will be tested at Tulane University. The Small Business...
Women’s health startup Joylux raises more cash, lands in Gwyneth Paltrow’s Goop store
From geekwire.com Joylux, a Seattle startup that aims to improve women’s sexual health with a wellness device, has raised an additional $7 million. Joylux plans to use the money to bolster its sales team and scale the company. The additional Series A financing brings...
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
From istar-medical.com NORTH CHICAGO, Ill. and WAVRE, BELGIUM, July 20, 2022 – AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject® device, a next-generation minimally invasive...
Embera Wins $11.1M NIDA Grant to Develop Addiction Treatment
Embera NeuroTherapeutics has received an $11.1 million, 3-year grant from the NIH’s National Institute on Drug Abuse (NIDA) to support continued clinical development of its cocaine addiction treatment EMB-001. “With this support, we are excited to continue the...